OptimizeRx (NASDAQ:OPRX) Stock Keeps “Buy” Rating at B. Riley Financial

OptimizeRx (NASDAQ:OPRX)‘s stock had its “buy” rating reaffirmed by investment analysts at B. Riley Financial in a research report issued on Thursday, Benzinga reports. They currently have a $10.50 price objective on the stock, down from their prior price objective of $11.00. B. Riley Financial‘s price target suggests a potential upside of 58.16% from the stock’s current price.

OPRX has been the subject of several other reports. Stifel Nicolaus lowered their price objective on shares of OptimizeRx from $12.00 to $11.00 and set a “buy” rating for the company in a report on Thursday. Citizens Jmp raised their target price on OptimizeRx from $9.00 to $11.00 and gave the company a “market outperform” rating in a research note on Friday, August 14th. Wall Street Zen cut OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. Citigroup restated a “market outperform” rating on shares of OptimizeRx in a research report on Tuesday, October 27th. Finally, Weiss Ratings raised OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, August 25th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $11.36.

OptimizeRx Trading Down 25.8%

NASDAQ OPRX traded down $2.31 during trading on Thursday, hitting $6.64. The company had a trading volume of 344,001 shares, compared to its average volume of 349,433. The company’s fifty day moving average is $8.43 and its 200-day moving average is $7.24. OptimizeRx has a one year low of $4.54 and a one year high of $16.37. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 0.14. The company has a market cap of $125.08 million, a price-to-earnings ratio of 28.98 and a beta of 1.20.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Wednesday, November 11th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.04. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. The firm had revenue of $21.61 million for the quarter, compared to analyst estimates of $21.19 million. On average, sell-side analysts predict that OptimizeRx will post 0.49 earnings per share for the current year.

Institutional Investors Weigh In On OptimizeRx

Hedge funds and other institutional investors have recently made changes to their positions in the business. Royce & Associates LP lifted its stake in shares of OptimizeRx by 20.7% in the 3rd quarter. Royce & Associates LP now owns 1,315,057 shares of the company’s stock worth $10,981,000 after purchasing an additional 225,659 shares during the period. Rice Hall James & Associates LLC increased its holdings in OptimizeRx by 1.9% during the first quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock valued at $3,780,000 after buying an additional 11,247 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in OptimizeRx by 22.3% during the first quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock valued at $3,540,000 after buying an additional 102,661 shares during the last quarter. AWM Investment Company Inc. bought a new position in OptimizeRx in the second quarter worth approximately $1,375,000. Finally, Renaissance Technologies LLC raised its position in OptimizeRx by 633.2% in the first quarter. Renaissance Technologies LLC now owns 216,856 shares of the company’s stock worth $1,362,000 after acquiring an additional 187,278 shares during the period. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx News Summary

These are some of the OPRX news items that stood out recently:

• Positive Sentiment: Q3 2026 adjusted earnings were $0.20 per share, above estimates of $0.16–$0.18. Revenue of about $21.6 million also topped the $21.19 million consensus. Zacks Q3 earnings report
• Neutral Sentiment: Stifel Nicolaus lowered its price target from $12 to $11 but maintained its Buy rating. The target cut is a cautionary signal, though the firm remains positive on the shares. Stifel Nicolaus recommendations
• Negative Sentiment: OptimizeRx guided to FY 2026 revenue of $87 million–$93 million, below the $96.2 million analyst consensus. This weaker-than-expected outlook could overshadow the quarterly beat. Company results and guidance

OptimizeRx Company Profile

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey. The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement.